Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats.

@article{Shan2013AlterationOT,
  title={Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats.},
  author={Chun-yan Shan and Jae Heon Yang and Yu Kong and Xiaoqi Wang and Miao Yan Zheng and Y. G. Xu and Yun Wang and Hui Zhu Ren and Bao Cheng Chang and Lianmin Chen},
  journal={The Journal of endocrinology},
  year={2013},
  volume={218 3},
  pages={255-62}
}
For centuries, Berberine has been used in the treatment of enteritis in China, and it is also known to have anti-hyperglycemic effects in type 2 diabetic patients. However, as Berberine is insoluble and rarely absorbed in gastrointestinal tract, the mechanism by which it works is unclear. We hypothesized that it may act locally by ameliorating intestinal barrier abnormalities and endotoxemia. A high-fat diet combined with low-dose streptozotocin was used to induce type 2 diabetes in male… CONTINUE READING